Study design: Postal questionnaire survey. Objective: To examine the current use of hormone replacement therapy (HRT) in a sample of menopausal women with spinal cord injury (SCI). Setting: National Spinal Injuries Centre (NSIC), Stoke Mandeville Hospital, Aylesbury, UK. Method: A postal questionnaire was sent to 94 women from the NSIC patient database who met the study inclusion criteria (wheelchair dependent, aged 49 years and above, last seen or heard from within the last 3 years).
Introduction
A woman is deemed to be postmenopausal if her last menstrual period occurred 12 or more months ago. 1 The menopause is associated with symptoms such as hot flushes, night sweats, sleep disturbances, emotional instability, anxiety, depression, vaginal dryness as well as increased risks of osteoporosis and cardiovascular disease. Hormone replacement therapy (HRT) has been used widely over the past few decades by postmenopausal women in many countries as an effective treatment for menopausal symptoms and urogenital atrophy. HRT has also been shown by several studies to reduce successfully the incidence of osteoporosis [2] [3] [4] and colorectal cancer. 2, 4, 5 Observational studies in the past have suggested that both combined oestrogen and progestogen and oestrogen alone HRT preparations reduce the risk of coronary heart disease (CHD) [6] [7] [8] [9] and cerebrovascular disease (CVD) [10] [11] [12] and are especially effective in secondary prevention in women with established CHD or CVD. However, more recent randomised controlled trials have disproved earlier beliefs and have failed to show these benefits. 2, [13] [14] [15] [16] They demonstrated that HRT does not offer any cardiovascular [13] [14] [15] or cerebrovascular 16 protection, but instead increases the risks of the ischaemic heart disease 2,17 and stroke. 2, 18 The same studies simultaneously confirmed the two well-known side effects of HRT: increased risk of breast cancer, 2, [19] [20] [21] [22] which rises with the duration of HRT 19 and is substantially greater in oestrogen-progestogen combined HRT; 20 and increased risk of thromboembolism, 2, 13, 23, 24 which seems to be highest in the first year of use. 24 Other reported side effects were increased risk of gall bladder diseases, 13 increased risk of ovarian cancer with continuous use of combined HRT 25 and increased risk of dementia in women aged 65 and older. 26 These new findings have caused much uncertainty among women and their doctors regarding the usage of HRT.
The risk-benefit ratio is even more complex in a woman with spinal cord injury (SCI). Immobilisation after SCI is associated with marked increase in bone resorption and only minor changes in bone formation, which result in loss of bone mineral density and osteoporosis in those parts of the skeleton that are no longer weight bearing. [27] [28] [29] The only exception is the lumbar spine, where bone mineral density is preserved or even increased with time since injury. [29] [30] [31] Studies have shown that the major sublesional bone loss occurs during the first 2 years after injury and at a slower rate thereafter, [30] [31] [32] with bone mineral density reaching fracture threshold between 1 and 5 years after injury. 32, 33 The loss of sensation and proprioception further increases the risk of pathological bone fractures, which adds to the morbidity, hospital readmissions and cost of treatment in patients with chronic SCI. [34] [35] [36] HRT could reduce the risk of fracture by slowing the further development of osteoporosis following menopause, 37 but no longitudinal studies have been carried out in women with SCI to confirm this. Other potential benefits of HRT in women with SCI could be in treating atrophic vaginitis and reducing the incidence of urinary tract infections, especially in women on indwelling or intermittent catheterisation, and in lowering the incidence of colorectal cancer. Conversely, being on HRT could further increase the thromboembolic risk, but there have been no studies to date that have assessed the additional risk of thromboembolism due to long-term immobility in women with SCI.
Risks and benefits of HRT are summarised in Table 1 .
There is very little information in the medical literature about the use of HRT by women with SCI. 38, 39 We found only one publication in the English literature, a multicentre study of self-reported reproductive health after SCI, which mentions the percentages of women on HRT, but not the main reasons for treatment or its duration. 40 We conducted a postal survey at the National Spinal Injuries Centre (NSIC), Stoke Mandeville Hospital to establish the uptake of HRT by women with longstanding SCI in our centre.
Materials and methods
The NSIC active patient database (database of patients who contacted or attended the Centre in the last 3 years) was searched for female patients aged 49 years and older who were regular wheelchair users (ASIA/Frankel grade A, B or C). 41, 42 The 94 women who met the study inclusion criteria were sent a 20-item postal questionnaire about current and previous HRT use, brief gynaecological history and basic demographic information.
Results
A total of 61 questionnaires were returned (response rate 65%). Two of these were excluded from the analysis, because the patients were functional walkers. In all, 59 valid questionnaires were analysed (effective response rate 62%).
Sample characteristics
All 59 patients were regular wheelchair users, 22 were tetraplegic and 37 paraplegic, 31 had a complete injury (ASIA/Frankel grade A) and 28 incomplete (ASIA/ Frankel grade B or C). The mean age of the sample was 59 years, with the age range 49-72 years, mean age at injury was 28 years (range 0-53) and mean time since injury was 31 years (range 9-59). At the time of the survey, 50 women were menopausal, with the mean age of 60 years and range 50-72 years. Nine women were premenopausal, with the mean age of 52 years and range 49-55 years.
HRT use
The summary of HRT use is given in Table 2 .
Of the 50 menopausal women, 11 (22%) were on HRT at the time of the survey and another 11 (22%) had been on HRT in the past, but had discontinued the treatment before the survey. The main reasons for starting HRT were menopausal symptoms in 14 women (28%) and osteoporosis prevention in eight women (16%). The mean age when HRT was started was 48.8 years (range [38] [39] [40] [41] [42] [43] [44] [45] [46] [47] [48] [49] [50] [51] [52] [53] [54] [55] [56] . Mean duration of treatment was 10.6 years in the 11 women still on HRT (range 6-15) Possible additional benefit in postmenopausal women with spinal cord injury and 7.2 years in the 11 women no longer on HRT (range 0.5-15). In the 11 women still on HRT, the main reasons for starting HRT were menopausal symptoms in six (12%) and osteoporosis prevention in five (10%). Of the 11 women who had discontinued HRT, eight (16%) had been on it for menopausal symptoms and three (6%) for osteoporosis prevention. The main reasons for stopping HRT in these women were side effects in four cases, lack of desired effect on menopausal symptoms in three cases, unspecified personal choice in two cases and newly diagnosed breast cancer in two women.
Of the 28 menopausal women (56%) who had never been on HRT, 20 had either enquired about it or had been offered HRT, but decided against it. Of the nine women who were still premenopausal at the time of the survey, four would consider using HRT.
The majority of women in our sample were started on HRT or had discussed it with their general practitioners. Only five had discussed it with their spinal consultant and/or a gynaecologist.
Other medication
Other medications taken for osteoporosis prevention were biphosphonates by five women, of whom three were on HRT at the same time, and calcium supplements by 14 women, of whom four were on HRT as well.
Discussion
The results of our study show that 22% of menopausal women in our sample were on HRT at the time of the survey. This percentage of current HRT users is somewhat higher than the 20% reported in 1999 in the general population in Great Britain, 43 but much lower than the estimated 41% of current users in a general population sample in the USA in 1997. 44 The combined number of current and past users in our sample (44%) is higher than in the USA sample of SCI women (35% preinjury and 26% postinjury), 40 but lower than the 60% reported in a 2002 British community survey of women aged 51-57 years. 45 The average duration of treatment in our sample was more than twice as long as in the general population, probably because almost half of the women on HRT in our study were taking it for osteoporosis prevention. Another interesting finding was that a much higher percentage of women in our sample have considered or at least discussed HRT use with their doctors as compared with the general population in Great Britain, 43 probably due to the potential additional benefits of HRT in relation to osteoporosis after SCI. It is worth noting that the data collection for this study took place before the latest results of the Women's Health Initiative 2 and Million Women Study 20 were published. The proportion of women who decide to start or continue HRT may have changed since then, both in the general population 44, 46 and in women with SCI.
It remains a difficult decision for women with SCI and their doctors to decide whether to use HRT for menopause symptom control and what treatment they should adopt to reduce the risk of osteoporosis and future bone fractures. Evidence from large randomised controlled studies, especially the Heart and Estrogen/ progestin Replacement Study (HERS) 13, 14 and the Women's Health Initiative (WHI) Study, 2,25,26 demonstrating increased incidence of CHD, CVD, breast cancer, thromboembolism, gall bladder diseases, ovarian cancer and dementia associated with the use of HRT, has made decision making even more complex. A number of factors need to be taken into consideration in making the final decision: concurrent problems affecting quality of life, such as vasomotor, psychological and other menopausal symptoms, the absolute risk of fracture based on the individual's risk assessment, clinical findings, personal and family history as well as the duration and cost of potential treatment. [47] [48] [49] [50] [51] The majority of patients in our sample were on HRT for menopausal symptom control -about two-thirds of all users and just over half of current users. There is very little information in the medical literature about the menopause in women with SCI, 39, 40 but the few studies we found suggest that some menopausal symptoms may be worse after SCI. HRT is well established and widely accepted as the only effective treatment for menopausal symptoms in the general population and there is no reason why the same would not apply to women with SCI.
A third of our responders who were or had been on HRT and almost half of the current HRT users were taking it for osteoporosis prevention. The mean duration of treatment in this subgroup was longer than in the subgroup taking HRT for menopausal symptoms. Most studies looking at the effectiveness of HRT in osteoporosis prevention have been carried out on postmenopausal ambulatory women. [52] [53] [54] No published studies, to our knowledge, have included women with SCI. As the bone mineral density in women with SCI is already reduced due to their paralysis, 31, 37 additional bone loss after menopause could put them at higher fracture risk.
There have been reports on higher fracture incidence with increasing age and time postinjury, especially in women, 40, 55 but the additional postmenopausal risk has not been quantified. 38 It is our personal experience that patients often ask clinicians' opinion on HRT and osteoporosis. To identify the specific risks and benefits for a woman with SCI, studies would specifically have to recruit peri-and postmenopausal women with SCI. Such trials would be difficult to set-up. With only approximately 20% of the traumatic SCI population being women, 56, 57 recruitment would take a long time. Follow-up would need to be of a sufficient length to analyse adequately the risks and benefits for women with SCI. The sample population would be heterogeneous, as the subjects would have had different bone densities prior to sustaining their SCI, as well as spinal cord lesions located at different levels and of varying severity. The management and treatment of the patients at various medical centres are different. All these confounding factors would need to be taken into account when setting up a study. Patient recruitment would be even more difficult now, in view of the latest randomised controlled trial results in ablebodied women. Two big HRT trials, the WHI 2 and the HABITS, 22 had to be stopped prematurely because they exceeded the stopping boundary for adverse effects and the global index statistics showed that risks exceeded benefits. For the same reason, early in March this year the oestrogen arm of the WHI 58 was stopped prematurely and the participants were asked to start the follow-up phase. It is very unlikely that a randomised controlled trial in women with SCI could be carried out and the decision to commence or continue HRT would need to be in each individual case after a risk assessment. The current recommendations by the British Committee on Safety of Medicines (CSM) 59 and the American Food and Drug Administration (FDA) 60 are that HRT be used for short-duration treatment of moderate and severe menopausal symptoms and not as a first-line prevention of osteoporosis.
HRT is currently the only effective treatment for menopausal symptoms. However, there are other drugs for postmenopausal osteoporosis prevention and treatment. [61] [62] [63] [64] [65] Calcium supplements and vitamin D, calcitonin, thiazide diuretics, selective oestrogen receptor modulators (SERMs), biphosponates and recombinant human parathyroid hormone have been shown to reduce osteoporosis in postmenopausal women, but they have not been studied in women with SCI. Most antiresorptive drugs can reduce the risk of osteoporotic vertebral fractures, but only few have been proven to reduce the risk of nonvertebral fractures as well, which would be needed for the SCI population. Bisphosphonates, such as alendronate, risedronate, etidronate and tiludronate, reduce osteoclast-mediated resorption and bone remodelling and can reduce the relative risks of both vertebral and nonvertebral fractures. 66, 67 They are the only medications for which we found some published reports of use in people with SCI, with possibly promising results. [68] [69] [70] Thiazide diuretics were shown to slow down cortical bone loss in healthy postmenopausal women 71 and in healthy older adults 72 but with modest effects overall, 71, 72 somewhat stronger in women. 72 A new bone formation enhancing drug, recombinant human parathyroid hormone, which has recently been approved in the USA and Europe, has been shown to increase bone mass and reduce incidence of both vertebral and nonvertebral fractures. [73] [74] [75] In an effort to achieve stronger therapeutic effects, combination treatments for osteoporosis are beginning to be explored, and while it seems that combinations of some antiresorptive treatments may have synergistic effect, 76 optimal ways of combining them with bone formation stimulating drugs without reducing the anabolic effect of the latter are yet to be found. 77 Studies in able-bodied postmenopausal women show that exercise may be an effective nonpharmacological way of slowing the rate of bone loss. 78 Exercise has been widely used in people with SCI for its many benefits, but with somewhat disappointing results in osteoporosis prevention. Studies in patients with SCI showed physical therapy, including standing, walking, weight-bearing exercise and functional electrical stimulation, to be either ineffective in preventing bone loss below the level of injury [79] [80] [81] [82] [83] or partly effective and only with regular and sufficient use, 84, 85 which is rarely feasible in everyday life. As with HRT, none of the above drugs are without their side effects, and the final decision on which treatment is best for a particular patient will depend on a detailed risk-benefit assessment in each individual case.
Conclusions
At the time of the survey, 22% of menopausal women in our sample were on HRT and another 22% had been on HRT at some point, but had discontinued its use. The main indications for starting HRT were menopausal symptoms and osteoporosis prevention. In the light of the recent published work on HRT in able-bodied women, it would seem appropriate to recommend HRT for short-term relief of menopausal symptoms, but to consider alternative managements for osteoporosis prevention in women with SCI.
